Nesiller Genetic provides evidence-based precision oncology solutions from diagnosis through treatment planning by combining companion diagnostics (CDx), country-specific clinical trial matching, and internationally validated bioinformatics analyses.
Our comprehensive oncology testing portfolio is aligned with ESMO, ASCO, and NCCN guidelines and focuses on identifying clinically actionable treatment options.
Cancers are not all the same. Even tumors that develop in the same organ may have different genetic and molecular characteristics from one patient to another. These differences may affect disease behavior and response to treatment. Therefore, each patient should be evaluated by taking their individual characteristics into consideration. Comprehensive Genomic Profiling (CGP) examines the genetic makeup of a tumor on a broad scale, helping to identify patient-specific molecular characteristics and support the evaluation of personalized treatment options.
Applications of Oncology Testing:
Developing Targeted Treatment Strategies
Monitoring Treatment Resistance
Monitoring and Prognosis
Early Detection and Screening
Hereditary Risk Assessment
What Do Oncology Tests Provide?
They reveal the genetic and molecular profile of the tumor.
They identify targetable genetic alterations and support personalized treatment decisions.
They provide information about biological characteristics that may affect treatment response or the development of treatment resistance.
They may support the identification of relevant biomarkers for clinical trials and new treatment options.
COMPREHENSIVE CAPABILITIES ACROSS THE CANCER JOURNEY
A comprehensive genetic test that analyzes hereditary cancer risk by identifying germline variants and supports risk assessment and personalized treatment strategies.
A comprehensive genetic testing panel that assesses hereditary cancer risk by identifying germline variants and supports hereditary cancer screening for individuals.
A next-generation sequencing (NGS) test that analyzes somatic mutations, gene fusions, and copy number alterations in hematologic malignancies and sarcomas to provide a comprehensive genomic profile and support targeted therapy selection.
Solution-focused panels designed to detect genetic alterations specific to tumor types. NGS, IHC, and PCR-based technologies are used to support analyses, support tumor characterization, treatment monitoring, and targeted therapy selection.
Testing panels designed to accurately classify hematologic diseases. Analyses performed using FISH and RT-PCR methods support clinical decision-making.
Comprehensive genomic profiling test that integrates whole exome (WES) and transcriptome analysis to provide meaningful insights into tumor biology.
Offers comprehensive genomic profiling from tissue or liquid biopsy to identify clinically relevant genomic alterations and support targeted therapy selection.
Comprehensive genomic profiling to analyze clinically relevant and actionable biomarkers and support treatment selection.
Disease-focused panels that detect genetic alterations specific to tumor types and support diagnosis, prognosis, and treatment planning.
Supports fast, reliable, and accurate analysis of actionable biomarkers to guide targeted therapy decisions.
A comprehensive panel test that analyzes tumor DNA in liquid biopsy (ctDNA) samples to identify genomic alterations and support treatment decisions.
A comprehensive panel test that analyzes tumor DNA in liquid biopsy (ctDNA) samples to identify genomic alterations and support treatment response monitoring.
A minimal residual disease (MRD) test designed to detect ctDNA in blood samples to monitor treatment response and detect molecular recurrence early.
A longitudinal monitoring solution that analyzes ctDNA in blood samples during and after treatment to detect molecular recurrence and support early intervention.
A minimal residual disease (MRD) test designed to detect ctDNA in blood samples to monitor treatment response, detect molecular recurrence early, and support prognosis.
A solution designed to monitor disease status and predict prognosis through ctDNA analysis for informed clinical decision-making.
Through technology transfer, Nesiller Genetic performs world-class oncology testing in its own laboratory using technologies from Illumina (USA) and Roche (Switzerland), two global leaders in molecular diagnostics and life sciences. Since 2021, these internationally recognized technologies have enabled us to deliver high-quality testing in accordance with global standards.
Our portfolio includes CAP-accredited comprehensive genomic profiling (CGP) assays, tumor-specific panels, and single biomarker tests performed on blood, tissue, and liquid biopsy samples.
Our FOCUS Oncology tests combine NGS technology with internationally validated bioinformatics analysis platforms to deliver personalized genomic insights. In addition, through collaborations with global leaders in genomics, including Foundation Medicine, Natera, and Roche, selected tests are performed at internationally recognized reference laboratories.
*NGS FOCUS is a trademark of Nesiller Genetik Tanı ve Bilgi Hizmetleri A.Ş.
For information about test options not listed here, please contact our team.
19 Mayıs Mah. Çoruh Sok. No:32/1 Fulya, 34394 Şişli / Istanbul, Turkey
Monday - Friday 09:00 - 18:00 Saturday 09:00 - 14:00
